Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at RBC from Outperform to Sector Perform. $30 price target. Expect lower orders from Chinese communications equipment makers.
downgraded at Goldman to Neutral. $53 price target. Stock is already pricing in higher met coal.
( CPNO) downgraded at Barclays to Equal Weight from Overweight due to slow distribution growth prospects. Maintain $29 price target.
upgraded at Jefferies from Hold to Buy. $17 price target. Company has pricing power in its core markets.
downgraded at Deutsche from Buy to Hold. Valuation call, based on an $11 price target.
Jack in the Box
upgraded at RBC from Sector Perform to Outperform. $28 price target. Checks show improving fast-food sales.
rated new Overweight at Morgan Stanley. $37 price target. Company is most leveraged to the petrochemical industry, which is likely on the cusp of a super-cycle.
Millicom Intl Cellular
( MICC) downgraded at Citi to Hold from Buy on valuation. Maintain $100 price target.
downgraded at UBS from Buy to Neutral. Valuation call, based on a $23 price target.
upgraded at Wells to Outperform. Proposed rate case appears favorable for the company.
rated new Hold at Citigroup. Coverage of PEP now started with a Hold rating. $71 price target. Company delivers consistent growth, but execution needs to improve in the beverages space.
Smurfit-Stone Container Corp
( SSCC) initiated at BofA/Merrill with a Neutral rating and $24 price target. One of the industry's leading manufacturers of containerboard, with improved fundamentals following bankruptcy.
initiated at BofA/Merrill with a Neutral rating and $57 price target. Solid fundamentals but TW will see its float increase by 35% due to lockup expirations.
downgraded at Barclays to Equal Weight from Overweight. Revenue and margin improvement already priced into shares. Price target sunk to $25 from $28.
STOCK COMMENTS / EPS CHANGES
estimates, target boosted at Goldman. Shares of AGN now seen reaching $84. Estimates also upped, given early FDA approval for Botox to treat migraines. Buy rating.
estimates cut, target boosted at UBS. Shares of AIG now seen reaching $45. On the other hand, estimates were cut, given the conversion of preferred shares. Neutral rating.
target raised at Goldman. Shares of CHKP now seen reaching $48. Company like to post a very strong quarter. Buy rating.
numbers cut at Morgan Stanley through 2012. Company likely to have fewer subscribers and also face higher programming and operating costs. Equal-weight rating.
estimates upped at Morgan Stanley through 2013. Company was bullish about comp sales trends at its recent analyst meeting. Equal-weight rating.
price target higher at BofA/Merrill. ENR price target surged to $85 from $75. Despite large run up recently, shares have more room to grow. Maintain Buy rating.
target reduced at FBR. Shares of FHN now seen reaching $11. Underlying credit trends have deteriorated. Market Perform rating.
estimates changed at Credit Suisse. GE 2010 EPS estimate raised to $1.13, 2011 cut to $1.32. Could see downside in Power. Maintain Outperform rating and $22 price target.
estimates reduced at Morgan Stanley through 2012. Company seeing lower wind shipments and demand from the broader energy infrastructure market. Overweight rating and $22 price target.
numbers raised at Goldman. Shares of GE now seen reaching $19. Estimates also raised, given better aerospace demand and a lower expected tax rate. Buy rating.
numbers upped at Goldman through 2012. Company is seeing better automotive and industrial sales. Neutral rating and new $53 price target.
( HS) estimates, target raised at UBS. Shares of HS now seen reaching $29. Estimates also increased, following the Bravo acquisition. Neutral rating.
estimates, target boosted at JP Morgan. Shares of IBM now seen reaching $150. Estimates also upped, as checks suggest higher IT spending. Overweight rating.
estimates increased at Oppenheimer through 2012. Company is seeing business growth accelerate. Perform rating.
cut from Top Picks Live at Citigroup. Valuation call, as consensus estimates have caught up with the company's earnings power. $37 price target.
Johnson & Johnson
numbers raised at Citigroup. Shares of JNJ now seen reaching $70. Company seeing better current credit trends. Buy rating.
target upped at Goldman to $29. Latest credit data shows better delinquency and charge-off trends. Neutral rating.
numbers reduced at Goldman. Shares of LPS now seen reaching $27. Estimates also cut, Foreclosure delays will hurt the company. Neutral rating.
target, estimates boosted at Barclays. MAN price target increased to $66 from $62. MAN remains top pick in staffing sector. 2010 and 2011 EPS estimates lifted to $1.40 and $2.66, respectively. Maintain Overweight rating.
target raised at UBS. Shares of MO now seen reaching $27. Company has pricing power and should benefit from lower litigation risk. Buy rating.
target raised at Goldman. Shares of PFE now seen reaching $20. Company could continue to grow through acquisitions like KG. Buy rating.
numbers increased at Goldman through 2012. Company is executing well in a difficult environment. Neutral rating and new $17 price target.
target increased at Citigroup to $24. Analyst seeing better demand for the company's top products. Buy rating.
target lowered at UBS. Shares of SYK now seen reaching $55. Prices could be flat in joints and overall sales growth down. Buy rating.
V F Corp
price target boosted at BofA/Merrill. VFC price target boosted to $95 from $90, as the company's Jeanswear business could growth above expectations. Maintain Buy rating.
price target boosted at Barclays to $76 from $70. Expecting strong numbers when it reports tonight. Maintain Equal Weight rating.
price target raised at Barclays to $34 from $30. Maintain Equal Weight rating. Expecting solid Naming Services results.
estimates, target lowered at Citigroup. Shares of WMT now seen reaching $63. Estimates also cut, given the company's higher CapEx guidance. Buy rating.
estimates increased at Keybanc through 2012. Permian Basin should continue to drive growth. Buy rating and $85 price target.
This article was written by a staff member of TheStreet.